Giovanni Caforio (Christopher Goodney/Bloomberg via Getty Images)

October 5, 2020 07:10 AM EDTUpdated 11:07 AM

Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout

John Carroll

Editor & Founder

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

Strand Therapeutics reports promising start for mRNA cancer therapy

A new dawn for psychedelics? Compass could be the first to find out

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

InflaRx cans Gohibic development after skin disease trial stopped for futility

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation